On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

Table 4 Predictive value of hepatitis B e antigen titer as well as its declined value at week 12 and 24 for hepatitis B e antigen seroconversion after 96-wk nucleos(t)ide analogues therapy

Factors	ROC		Sensitivity (95%CI)	Specificity (95%CI)	PPV (95%CI)	NPV (95%CI)
	AUROC (95%CI)	P value
Week 12
HBeAg decline > 1.8 lg PEIU/mL	0.767 (0.623-0.911)	0.001	0.6 (0.32-0.88)	0.87 (0.78-0.96)	0.53 (0.26-0.79)	0.9 (0.82-0.98)
Week 24
HBeAg < -0.5 lg PEIU/mL	0.828 (0.712-0.944)	< 0.001	0.67 (0.40-0.94)	0.92 (0.84-0.99)	0.67 (0.40-0.94)	0.92 (0.84-0.99)
HBeAg decline > 2.2 lg PEIU/mL	0.814 (0.676-0.953)	< 0.001	0.73 (0.48-0.99)	0.9 (0.82-0.98)	0.65 (0.39-0.90)	0.93 (0.86-1.00)
Combined the above	0.928 (0.791-1.000)	< 0.001	0.88 (0.58-1.00)	0.98 (0.94-1.00)	0.88 (0.58-1.00)	0.98 (0.94-1.00)

HBeAg: Hepatitis B e antigen; SC: HBeAg seroconversion; AUROC: Area under the receiver operating characteristic curve; PPV: Positive predictive value; NPV: Negative predictive value.